Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 5/20 | 0.59 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RORA | P35398 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358368 | 0.95 | MOGAT2 (0.61) | MOGAT2MGAT2APPMAPTMEN1 | |
| SCHEMBL5370221 | 0.91 | MOGAT2 (0.57) | MOGAT2MGAT2APPMAPTMEN1 | |
| SCHEMBL5361301 | 0.90 | MOGAT2 (0.56) | MOGAT2MGAT2GSK3BLRRK2 | |
| SCHEMBL5362785 | 0.90 | MOGAT2 (0.56) | MOGAT2MGAT2APPMAPTMEN1 | |
| SCHEMBL5357745 | 0.90 | MOGAT2 (0.58) | MOGAT2MGAT2GSK3BLRRK2PRKDC | |
| SCHEMBL5358533 | 0.90 | MOGAT2 (0.56) | MOGAT2MGAT2APPMAPTMEN1 | |
| SCHEMBL5367769 | 0.90 | MOGAT2 (0.56) | MOGAT2MGAT2APPMAPTMEN1 | |
| SCHEMBL5369913 | 0.90 | MOGAT2 (0.56) | MOGAT2MGAT2MEN1ALOX15MAPK1 | |
| SCHEMBL7140033 | 0.90 | MOGAT2 (0.56) | MOGAT2MGAT2APPMAPTMEN1 | |
| SCHEMBL5362279 | 0.89 | MOGAT2 (0.57) | MOGAT2MGAT2APPMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| US-6506763-B2 | Useful in prevention and treatment of protein kinase related disorders such as cancer | SUGEN, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | MOGAT2 1159/4885MGAT2 4714/4885APP 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.